 |
4 Diseases |  |
0 Trials |
|
0 Trials |  |
7 News |  |
- | Journal: Monoclonal antibodies and antibody-drug conjugates as emerging therapeutics for breast cancer treatment. (Pubmed Central) - Jul 31, 2023
The creation of novel technologies utilizing modified antibodies, such as fragments, conjugates, and multispecific antibodies, must be a central focus of future studies. This review will help scientists working on developing mAbs to treat cancers more effectively.
- Rexomun (ertumaxomab) / Trion Pharma
Enrollment change, Trial termination, Metastases: Open Label, Dose Escalating Study With Ertumaxomab In Patients With HER-2/Neu Expressing Advanced Solid Tumors (clinicaltrials.gov) - May 5, 2016
P1/2, N=14, Terminated, Sponsor: Krankenhaus Nordwest
This review will help scientists working on developing mAbs to treat cancers more effectively. N=24 --> 14 | Active, not recruiting --> Terminated
- Rexomun (ertumaxomab) / Trion Pharma
Trial primary completion date, Metastases: Open Label, Dose Escalating Study With Ertumaxomab In Patients With HER-2/Neu Expressing Advanced Solid Tumors (clinicaltrials.gov) - Aug 13, 2015
P1/2, N=24, Active, not recruiting, Sponsor: Krankenhaus Nordwest
N=24 --> 14 | Active, not recruiting --> Terminated Trial primary completion date: Jun 2015 --> Jun 2016
- Rexomun (ertumaxomab) / Trion Pharma
Enrollment closed, Trial primary completion date, Metastases: Open Label, Dose Escalating Study With Ertumaxomab In Patients With HER-2/Neu Expressing Advanced Solid Tumors (clinicaltrials.gov) - Mar 25, 2015
P1/2, N=24, Active, not recruiting, Sponsor: Krankenhaus Nordwest
Trial primary completion date: Jun 2015 --> Jun 2016 Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2015 --> Jun 2015
- Rexomun (ertumaxomab) / Trion Pharma
New P1/2 trial, Metastases: Open Label, Dose Escalating Study With Ertumaxomab In Patients With HER-2/Neu Expressing Advanced Solid Tumors (clinicaltrials.gov) - Apr 1, 2012
P1/2, N=24, Recruiting, Sponsor: Krankenhaus Nordwest